Browse studies

Find your next paid study

4 recruiting studies matching your filters

A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo

The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the i…

Non-segmental Vitiligo

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Elixiron Immunotherapeutics (Hong Kong) Ltd.NCT07223229

Phase 2

A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when…

VitiligoNon-Segmental Vitiligo (NSV)

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Eli Lilly and CompanyNCT07533019

Phase 2

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

Non-segmental Vitiligo

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Derm Texas, PLLCNCT07105254

Phase 2

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in partic…

Non-segmental Vitiligo

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT07431177